U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07482085) titled 'Efavirenz for the Treatment of Creutzfeldt-Jakob Disease' on March 06.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of efavirenz in patients with Creutzfeldt-Jakob disease (CJD). A total of 246 eligible participants will be enrolled across 21 study centers nationwide. Participants will be randomly assigned in a 1:1 ratio to receive either efavirenz or placebo.
Participants in the efavirenz group will receive 200 mg once daily at bedtime for the first week, followed by an increased dose of 400 mg once daily thereafter. ...